Examining the Effect of Chamomile on Clinical Symptoms and Hormonal Parameters Among Patients With Polycystic Ovarian Syndrome
Objective: Polycystic ovarian syndrome is the most common cause of infertility and endocrine disorder among women due to anovulation. The aim of the present study is to investigate the effect of chamomile on oligomenorrhea and hirsutism symptoms as well as hormonal parameters among patients suffering from polycystic ovarian syndrome.
Materials and methods: The present study is a randomized clinical trial performed on 70 patients with diagnosis of polycystic ovarian syndrome according to Rotterdam criteria referring to the infertility clinic of a university hospital. The patients were randomly assigned into intervention and control groups, with the former receiving two chamomile capsules 500 mg for three months, and the latter receiving two placebo capsules for 3 months. Both groups were evaluated in terms of laboratory parameters (FBS, LDL, and testosterone) on the third day of first and third cycles. The collected data were analyzed by SPSS 20.
Results: The mean age, body mass index, marital status, history of infertility, and pregnancy rate showed no significant difference between the two groups. In the chamomile group, clinical symptoms of hirsutism (p<0.001) and oligomenorrhea (p=0.048) decreased following the treatment, but significant difference was found between the two groups only in hirsutism symptoms (p=0.028). Regarding the parameters of FBS (p=0.06), HDL (p=0.224), cholesterol (p=0.99), triglyceride (p=0.106), testosterone (p=0.894), and LDL (p=0.61), no significant difference was observed between the two groups. Nevertheless, following the treatment, testosterone decreased in both placebo (p=0.005) and chamomile (p=0.001) groups.
Conclusion: overall, the chamomile therapeutic regimen has relatively been able to mitigate the clinical symptoms and testosterone levels in patients suffering from polycystic ovarian syndrome. Use of chamomile plant as a simple, inexpensive, and effective measure can be suggested for improving and treating patients with PCOS after confirmation by further studies.
2. Arslanian SA, Witchel SF. Polycystic ovary syndrome in adolescents: is there an epidemic? Current Opinion in Endocrinology, Diabetes and Obesity. 2002; 9: 32-42.
3. Boomsma C, Eijkemans M, Hughes E, Visser G, Fauser B, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006; 12:673-83.
4. Witchel SF, Oberfield SE, Peña AS. Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. J Endocr Soc 2019; 3: 1545-73.
5. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011; 2.
6. Huber-Buchholz M-M, Carey D, Norman R. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999; 84: 1470-4.
7. Janatan S.Breek. Novak’s Gynecology. 16th edition. Lippincott Williams & Wikins.
8. Pundir J, Charles D, Sabatini L, Hiam D, Jitpiriyaroj S, Teede H, et al. Overview of systematic reviews of
non-pharmacological interventions in women with polycystic ovary syndrome. Hum Reprod Update 2019; 25: 243-56.
9. Liao W-T, Su C-C, Lee M-T, Li C-J, Lin C-L, Chiang
J-H, et al. Integrative Chinese herbal medicine therapy reduced the risk of type 2 diabetes mellitus in patients with polycystic ovary syndrome: A nationwide matched cohort study. J Ethnopharmacol 2019; 243: 112091.
10. Arentz S, Smith CA, Abbott J, Bensoussan A. Nutritional supplements and herbal medicines for women with polycystic ovary syndrome; a systematic review and meta-analysis. BMC Complement Altern Med 2017; 17: 1-14.
11. Srivastava JK, Pandey M, Gupta S. Chamomile, a novel and selective COX-2 inhibitor with anti-inflammatory activity. Life Sci 2009; 85: 663-9.
12. Cemek M, Kağa S, Şimşek N, Büyükokuroğlu ME,
Konuk M. Antihyperglycemic and antioxidative potential of Matricaria chamomilla L. in streptozotocin-induced diabetic rats. J Nat Med 2008; 62: 284-93.
13. El-Halawany AM, El Dine RS, Chung MH, Nishihara T, Hattori M. Screening for estrogenic and antiestrogenic activities of plants growing in Egypt and Thailand. Pharmacognosy Res 2011; 3: 107-13.
14. Johari H, Sharifi E, Mardan M, Kafilzadeh F, Hemayatkhah V, Kargar H, et al. The effects of a hydroalcoholic extract of Matricaria chamomilla flower on the pituitary-gonadal axis and ovaries of rats. International Journal of Endocrinology and Metabolism 2011; 9: 330-4.
15. Marx TL, Mehta AE. Polycystic ovary syndrome: pathogenesis and treatment over the short and long term. Cleve Clin J Med 2003; 70: 31-3.
16. Karampoor P, Azarnia M, Mirabolghasemi G, Alizadeh F. The Effect of Hydroalcoholic Extract of Fennel (Foeniculum Vulgare) Seed on Serum Levels of Sexual Hormones in Female Wistar Rats with Polycystic Ovarian Syndrome (PCOS). Journal of Arak University of Medical Sciences 2014; 17: 70-78.
17. Arentz S, Abbott JA, Smith CA, Bensoussan A. Herbal medicine for the management of polycystic ovary syndrome (PCOS) and associated oligo/amenorrhoea and hyperandrogenism; a review of the laboratory evidence for effects with corroborative clinical findings. BMC Complement Altern Med 2014; 14: 1-19.
18. Karampoor P, Azarnia M, Mirabolghasemi G, Alizadeh F. The effect of hydroalcoholic extract of fennel (foeniculum vulgare) seed on serum levels of sexual hormones in female wistar rats with polycystic ovarian syndrome (PCOS). Journal of Arak University of Medical Sciences 2014; 17: 70-8.
19. Heidary M, Yazdanpanahi Z, Dabbaghmanesh MH, Parsanezhad ME, Emamghoreishi M, Akbarzadeh M. Effect of chamomile capsule on lipid-and hormonal-related parameters among women of reproductive age with polycystic ovary syndrome. J Res Med Sci 2018; 23: 33.
20. Zangeneh FZ, Minaee B, Amirzargar A, Ahangarpour A, Mousavizadeh K. Effects of chamomile extract on biochemical and clinical parameters in a rat model of polycystic ovary syndrome. J Reprod Infertil 2010 ;11: 169-74.
|Issue||Vol 16, No 4 (December 2022)|
|Chamomile Clinical Symptom Hormonal Parameters Polycystic Ovarian Syndrome|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|